2022年1月18日

Nucleix关闭55美元资金,公司对癌症治疗疾病早期检测算法通过液体活检,已获得5500万美元银团的领先的生命科学投资者超额认购资金。圆是由RA资本管理与新投资者的参与包括基金和账户管理的贝莱德,礼来亚洲企业,LYFE资本和MILFAM。现有投资者参与轮包括OrbiMed,兰姆,DSC投资,OCI琐辖Zisapel生物投资。Nucleix将利用融资的收益继续快速发展其独特的甲基化技术,称为EpiCheck,及其发展肺EpiCheck,引领产品为肺癌的早期诊断。克里斯HibberdCEONucleix听在一个拥挤的房间里窃窃私语“癌症的早期检测血液样本就像听耳语一个拥挤的房间里,你需要单独的一个微弱的信号从相当大的背景噪音,”Chris Hibberd说Nucleix的首席执行官。“EpiCheck最小化样品损失和背景噪音而检测分钟癌症表观遗传信号,敏感性大于其他技术,“Hibberd补充道。“这新资金使我们能够进一步证明的力量技术在肺癌,通过重点项目推进测试设计为高度敏感,容易部署和成本效益。“EpiCheck是一个敏感的技术检测甲基化的变化和兼容下一代测序(上天)和聚合酶链反应(PCR)平台。揭示新生物标志物Hibberd说Nucleix捷应用EpiCheck申请深刻的发现,揭示新的生物标记物,可用于癌症的早期检测和监控。反过来,这些发现可以先进使用PCR应用EpiCheck高度敏感的测试,与潜在的运行成本在中央和地方的实验室。肺EpiCheck是高度敏感,methylation-based血液化验为肺癌的早期诊断。 The test analyzes subtle, disease-specific changes in DNA methylation markers meeting the needs of its target population – current and past smokers – to catch cancer earlier when treatment can be most effective. Founded in Israel in 2008, Nucleix expanded its operations into the United States in May 2020 and appointed new executive and board leadership to support future growth. In October 2020, clinical data on the first generation of Lung EpiCheck was published in the European Respiratory Journal. The company is now developing an improved version of the assay and will initiate a prospective study to validate the test, with the goal of making it available in 2022. Aharona Shuali, M.D.VP MedicalNucleix Providing An Effective Screening Option “The U.S. Preventive Services Task Force (USPSTF) recently updated the screening guidelines for high-risk lung cancer patients to double the number of people who qualify for annual screening1, but a challenge remains as less than 10% of those eligible in the United States follow the guidelines today,” said Aharona Shuali, VP medical of Nucleix. “Lung EpiCheck has the potential to provide an effective screening option that increases compliance and drives more patients to follow guidelines in the United States – increasing chances of patients having a long-term benefit,” Shuali added. Lung EpiCheck is designed to provide a simple blood test that detects lung cancer at its earliest stages. The test utilizes NGS and PCR-based technology for highly sensitive analysis of subtle, disease-specific changes in DNA methylation markers. Lung EpiCheck is being developed for potential use in individuals with a history of smoking who are at high-risk of developing lung cancer, and do not comply with the guidelines for annual screening with low-dose computed tomography (LDCT) scans. The test is not yet commercially available. Nucleix’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The company’s non-invasive EpiCheck platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. The company is building an EpiCheck franchise, beginning with the Bladder EpiCheck testing kit, marketed in Europe for bladder cancer recurrence. Nucleix also is advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases. Nucleix